For the Inventor, By the Inventor

Enter assignee name

Sumitomo Pharmaceuticals Company Limited

Calculating rank

USPTO Granted Patents = 174

% Expired Patents = 14.9

Forward Citations = 2,901

Loading Chart...

Loading Chart...

324 inventors (with patents filed for the assignee):

Makoto Sunagawa (20 out of 33 patents)

Keiji Fujioka (19 out of 23 patents)

Naohito Ohashi (18 out of 30 patents)

4. Yoshihiro Takada (13 out of 21 patents)

5. Haruki Matsumura (12 out of 13 patents)

6. Shigeji Sato (12 out of 16 patents)

7. Atsuyuki Kojima (11 out of 20 patents)

8. Masami Muraoka (9 out of 12 patents)

9. Nobuhiko Tamura (9 out of 9 patents)

10. Keiichi Ono (9 out of 32 patents)

11. Akira Sasaki (8 out of 13 patents)

12. Ryu Nagata (8 out of 13 patents)

13. Masahumi Kitano (8 out of 8 patents)

14. Norihiko Tanno (8 out of 19 patents)

15. Akihiko Sano (7 out of 12 patents)

Core Competencies:

Cancer Therapies

Drug Formulations

Gene Therapies

Pharmaceutical Preparations

Bicyclic Compounds

Stable Gene Preparations

Recombinant Proteins

Neurotrophic Factors

Sustained Release

Pyridine Derivatives

CYP Genes

Antiviral Agents

174 patents: Sort by Forward Citations

1. 7449181 - Remedies for cancer (2008-11-11),

2. 7192608 - Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules (2007-03-20),

3. 7067528 - 1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative (2006-06-27),

4. 7052875 - Stable gene preparations (2006-05-30),

5. 7041297 - Tumor antigen peptides originating in cyclophilin B (2006-05-09),

6. 6951866 - Bicyclic pyrimidine compounds and therapeutic use thereof (2005-10-04),

7. 6939887 - Benzimidazolidinone derivatives (2005-09-06),

8. 6919361 - Five-membered-ring compound (2005-07-19),

9. 6902730 - Semaphorin gene: Semaphorin W (2005-06-07),

10. 6869609 - Method for treatment of renal failure and occlusive lesion of blood vessels by administration of hepatocyte growth factor (2005-03-22),

11. 6825317 - Cyclic tetrapeptide derivatives and pharmaceutical uses thereof (2004-11-30),

12. 6787560 - Serotonin reuptake inhibitor (2004-09-07),

13. 6759429 - Pyrrole derivatives (2004-07-06),

14. 6756358 - Therapeutic agent for cartilaginous diseases (2004-06-29),

15. 6756048 - Long time drug-sustained release preparation (2004-06-29),

Company Overview

Sumitomo Pharmaceuticals Company Limited, headquartered in Osaka, Japan, is a prominent player in the pharmaceutical industry, focusing on innovative therapies for various diseases. The company specializes in developing advanced cancer therapies, drug formulations, and gene therapies, aiming to improve patient outcomes through cutting-edge research. Its expertise extends to pharmaceutical preparations, including bicyclic compounds and recombinant proteins, as well as neurotrophic factors, positioning it as a leader in the field of pharmaceutical innovations.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

174 Patents

#83 in Osaka

#781 in Japan

#4,784 in the World

Sumitomo Pharmaceuticals Company Limited

Forward Citations = 2,901

324 inventors:

Makoto Sunagawa (20 out of 33 patents)

Keiji Fujioka (19 out of 23 patents)

Naohito Ohashi (18 out of 30 patents)

4. Yoshihiro Takada (13 out of 21 patents)

5. Haruki Matsumura (12 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sumitomo Pharmaceuticals Company Limited. Retrieved from https://idiyas.com/company/sumitomo-pharmaceuticals-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…